Status | Study |
Completed |
Study Name: A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723 Condition: Mucopolysaccharidosis II Date: 2012-05-17 Interventions: Drug: Idursulfase recombinant |
Active, not recruiting |
Study Name: Extension of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase (IT)in Conjunction With Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment Condition: Hunter Syndrome Date: 2011-12-15 Interventions: Drug: Idursulfase-IT Idursulfase-IT administered once monthly at the dose used in study HGT-HIT-045 via |
Completed |
Study Name: Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome Condition: Hunter Syndrome Date: 2011-10-06 Interventions: Other: No treatment |
Recruiting |
Study Name: Biomarker for Hunter Disease Condition: Lysosomal Storage Diseases Hunter Disease Date: 2011-04-04 |
Completed |
Study Name: To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients Condition: Mucopolysaccharidosis II Date: 2011-02-22 Interventions: Drug: GC1111_0.5mg/kg Drug: GC1111_1.0mg/k |
Completed |
Study Name: Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase® Condition: Hunter Syndrome Date: 2009-07-09 Interventions: Behavioral: Neurobehavioral testing |
Completed |
Study Name: A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® Condition: Hunter Syndrome Date: 2009-06-12 Interventions: Other: Control 3 dose cohorts |
Completed |
Study Name: An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients Condition: Hunter Syndrome Date: 2009-04-16 Interventions: Biological: Idursulfase Patients received idursulfase as prescribed by their physician following locally |
Terminated |
Study Name: Clinical Trial of Growth Hormone in MPS I, II, and VI Condition: Mucopolysaccharidosis I Mucopolysaccharidosis II Date: 2008-09-08 Interventions: Drug: Somatropin (DNA origin) The study starting dose of Nutropin AQ® will be 0.48 mg/kg/week divid |
Completed |
Study Name: Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase Condition: Hunter Syndrome Mucopolysaccharidosis II Date: 2008-02-28 Interventions: Biological: Idursulfase Solution for intravenous infusion, 0.5 mg/kg once-weekly |